Latest news
Published On: February 23rd, 2023Lyon, France – February 23, 2023 – ErVaccine Technologies, a French biotech company developing next-generation therapeutic vaccines and cellular immunotherapies in oncology, announced today the inaugural […]
Published On: January 5th, 2023- ErVaccine is developing a therapeutic vaccine and cell therapy technology potentially applicable to many types of cancers
- First vaccine […]
Published On: November 8th, 2022Paola Bonaventura, project leader at ErVaccine Technologies, has been giving a talk entitled “Human Endogenous Retrovirus (HERVs) Represent a Source of Shared Tumour Epitopes Inducing High Avidity Cytotoxic T cells […]
Published On: September 22nd, 2022Stéphane Depil, founder and CEO of ErVaccine Technologies, will give a talk entitled “Human Endogenous Retrovirus Represent a Source of Shared Tumor Epitopes Inducing High-Avidity Cytotoxic T cells for Cancer […]
Published On: September 22nd, 2022ErVaccine Technologies, in collaboration with Centre Leon Berard hospital / Cancer Research Center of Lyon, is thrilled to announce the selection of their research collaborative project (PRCE) grant proposal by […]
Published On: August 30th, 2022SENIOR COMPUTATIONAL BIOLOGIST POSITION
Background
ErVaccine Technologies is a start up company integrated in Centre Léon Bérard, Lyon, France, which develops new immunotherapeutic approaches targeting human endogenous retroviruses […]
Published On: June 29th, 2022ErVaccine Technologies, a preclinical-stage biotechnology company, announces the publication of a new paper in American Journal of Hematology : ‘HERVs characterize normal and leukemia stem cells […]
Published On: June 16th, 2022ErVaccine Technologies, a preclinical-stage biotechnology company, today announces the publication of a new paper in European Journal of Cancer journal: ‘Tumor burden and antigen-specific T cell magnitude represent major parameters […]
Publications & Abstracts
- Published On: December 17th, 2021